Kissei Pharmaceutical Co., Ltd.
JPX: 4547.T0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Tokyo Stock Exchange
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Mutsuo Kanzawa
- Employees
- 1,779
- Headquarters
- Matsumoto, Japan
- IPO year
- 2001
- Market cap
- ¥181.1B
- Website
- https://www.kissei.co.jp
Loading 4547…
Loading profile data…Frequently asked questions about 4547
What does Kissei Pharmaceutical Co., Ltd. (4547.T) do?
Kissei Pharmaceutical Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical products primarily in Japan. It offers Urief and Urief OD tablets for the treatment of dysuria; Glufast, Glubes, and Marizev tablets for type 2 diabetes; Darbepoetin Alfa BS and Epoetin Alfa BS injections for the treatment of renal anemi...
Where does 4547.T trade?
Kissei Pharmaceutical Co., Ltd. (4547.T) trades on the Tokyo Stock Exchange.
What sector is 4547.T in?
Kissei Pharmaceutical Co., Ltd. (4547.T) operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry.
Who is the CEO of Kissei Pharmaceutical Co., Ltd.?
Mutsuo Kanzawa is the chief executive officer of Kissei Pharmaceutical Co., Ltd. (4547.T).
Where is Kissei Pharmaceutical Co., Ltd. headquartered?
Kissei Pharmaceutical Co., Ltd. is headquartered in Japan.
Does 4547.T pay a dividend?
Yes — Kissei Pharmaceutical Co., Ltd. (4547.T) paid a trailing twelve-month dividend of JPY 160.00 per share. Frequency and ex-dividend dates are tracked on the dividends tab.
When did 4547.T go public?
Kissei Pharmaceutical Co., Ltd. (4547.T) completed its initial public offering in 2001.